In conclusion, these studies demonstrate that nilotinib and bosutinib can reduce the levels of α-Synuclein and p-Tau in peripheral tissues and inside the CNS, and are therapeutic candidates to treat gastrointestinal complications in α-Synucleinopathies and other neurodegenerative diseases. This evidence concerns the gene MAPT and neurodegenerative disease.